Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avutometinib + defactinib for recurrent low-grade serous ovarian cancer in Japanese patients
jRCT2021240021Phase 2Active, not recruiting
- Sponsor
- Verastem Oncology
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of avutometinib and defactinib in low-grade serous ovarian carcinoma (LGSOC), fallopian tube serous adenocarcinoma (FTC) and primary peritoneal cancer (PPC), sponsored by Verastem Oncology. Primary endpoint: Confirmed overall response rate. Started Nov 2024; status: active, not recruiting.
02
Drugs
avutometinibdefactinib
03
Conditions
low-grade serous ovarian carcinoma (LGSOC)fallopian tube serous adenocarcinoma (FTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on jRCT2021240021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021240021.